Dr. M. (Ken) Kengatharan is a co-founder and President & COO of Armetheon, Inc. a co-founder and former President & CSO of Altheos, Inc., and a co-founder and former Vice President, Pre-Clinical R&D of Athenagen, Inc. (re-named CoMentis, Inc), all three biopharmaceutical companies are based in San Francisco bay area. He is also a founder and General Partner at Atheneos Capital, a San Francisco bay area based evergreen healthcare incubator fund. During the last 14 years, Dr. Kengatharan has been critical to the development of multiple drug candidates (NCEs and re-purposed drugs) from concept to Phase II. Since setting-up his first company in the late 1990s, Dr. Kengatharan has been critical to raising more than $130 MM in private equity for five start-up companies. In 2004, Dr. Kengatharan co-founded Athenagen, Inc. (re-named CoMentis, Inc.) which in 2008 completed licensing and drug development collaboration deal with Astellas Pharmaceutical worth $760+ MM with an upfront payment of $100MM. He joined the company as its Vice-President of Pre-Clinical Research and Development and then became Vice-President of Translational Research and Scientific Affairs. His responsibilities included overseeing discovery research and pre-clinical drug development in cognition enhancement, inflammation, and angiogenesis, in addition to managing pre-clinical R&D operations in South San Francisco. Prior to joining CoMentis, he was a staff scientist in the Division of Cardiovascular Medicine at Stanford University, where he continued his affiliation as a visiting scientist until June 2013. Dr. Kengatharan has also served as Director of Corporate Development, and later, Vice President of Pre-Clinical R&D at OxoN Medica Inc., where he spearheaded pre-clinical drug development as well as R&D operations. He is currently a member of the board of directors at Armetheon, Inc., and previously a board observer at CoMentis, Inc., and Altheos, Inc. He has also served on the boards of EPi3, Athenagen, Inc., and Altheos, Inc., and as a member of the advisory board of Cardinal Free Clinics at Stanford University School of Medicine. In addition, he has been an advisor to Stanford’s SPARK program, a technology translation project for biotech ideas, since it was founded in 2006. Dr. Kengatharan is an author of several research articles and reviews in the vascular biology, inflammation, and ocular pharmacology areas, and has been invited to present at local and international scientific meetings covering topics in angiogenesis, inflammation, ocular drug delivery and biotech financing and start-ups. Dr. Kengatharan obtained his PhD in pharmacology from the University of London at the William Harvey Research Institute with Nobel laureate Sir John Vane and his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship. Thereafter, he held a post-doctoral position at the same institute as a recipient of a British Heart Foundation Fellowship.